Passa al contenuto
Merck

Engineering micro oxygen factories to slow tumour progression via hyperoxic microenvironments.

Nature communications (2022-08-03)
Weili Wang, Huizhen Zheng, Jun Jiang, Zhi Li, Dongpeng Jiang, Xiangru Shi, Hui Wang, Jie Jiang, Qianqian Xie, Meng Gao, Jianhong Chu, Xiaoming Cai, Tian Xia, Ruibin Li
ABSTRACT

While hypoxia promotes carcinogenesis, tumour aggressiveness, metastasis, and resistance to oncological treatments, the impacts of hyperoxia on tumours are rarely explored because providing a long-lasting oxygen supply in vivo is a major challenge. Herein, we construct micro oxygen factories, namely, photosynthesis microcapsules (PMCs), by encapsulation of acquired cyanobacteria and upconversion nanoparticles in alginate microcapsules. This system enables a long-lasting oxygen supply through the conversion of external radiation into red-wavelength emissions for photosynthesis in cyanobacteria. PMC treatment suppresses the NF-kB pathway, HIF-1α production and cancer cell proliferation. Hyperoxic microenvironment created by an in vivo PMC implant inhibits hepatocarcinoma growth and metastasis and has synergistic effects together with anti-PD-1 in breast cancer. The engineering oxygen factories offer potential for tumour biology studies in hyperoxic microenvironments and inspire the exploration of oncological treatments.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
Cocktail di inibitori delle fosfatasi 2, aqueous solution (dark coloration may develop upon storage, which does not affect the activity)
Sigma-Aldrich
PMA, for use in molecular biology applications, ≥99% (HPLC)
Sigma-Aldrich
Proteasi, Type XIV, ≥3.5 units/mg solid, powder
Sigma-Aldrich
Anti-actina, affinity isolated antibody, buffered aqueous solution
Sigma-Aldrich
IKK Inhibitor III, BMS-345541, IKK Inhibitor III, BMS-345541, CAS 445430-58-0, is a cell-permeable, potent, selective, and allosteric site-binding inhibitor of IKK-2 (IC₅₀ = ~ 300 nM).